Siga recently filed a Confidential Treatment form with the SEC regarding the BARDA contract which expires in 2020. The SEC accepted it.
This means that Siga is not required to publically divulge revenue they may receive from BARDA for the length of the contract.
The next piece of news should be about the completion of phase 3 testing and moving forward to file the NDA with the FDA for TPOXX, (the orthopox virus vaccine) for commercial distribution.
Typically the FDA will decide on approval within 6 months.
No comments:
Post a Comment